AssetMark Inc
IMNM icon

AssetMark Inc’s Immunome IMNM Stock Holding History

AssetMark Inc’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Buy
5,071
+536
+12% +$11.5K ﹤0.01% 1605
2026
Q1 		$99.2K Buy
4,535
+1,442
+47% +$32.1K ﹤0.01% 1543
2025
Q4 		$66.4K Sell
3,093
-271
-8% -$4.76K ﹤0.01% 1618
2025
Q3 		$39.4K Buy
+3,364
New +$33.5K ﹤0.01% 1713

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

AssetMark Inc's IMNM Position: Q2 2026 in Review

AssetMark Inc increased its Immunome (IMNM) stake by 12% in Q2 2026, buying an estimated $11.5K and bringing the position to 5,071 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #1605.

AssetMark Inc first reported a position in IMNM in Q3 2025 and has held it in 4 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • AssetMark Inc held 5,071 shares of Immunome worth $107K as of Q2 2026.
  • AssetMark Inc bought 536 Immunome shares in Q2 2026, an estimated $11.5K.
  • Immunome made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1605 holding.
  • AssetMark Inc first reported a position in Immunome in Q3 2025 and has held it in 4 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.